Companies: 10,795·Total market cap: $144.5T
Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

TNDMNASDAQHealthcare● Active
$18.47
$-0.87(-4.50%)
Market Cap$1.3B
P/E Ratio
52W High$29.65
52W Low$9.98

Tandem Diabetes Care, Inc. (TNDM) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

tndm · stock forecast · 39 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 39 Wall Street analysts in the past 3 months

SellBuy

Buy

39 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
25
Hold
14
Sell
0
Strong Sell
0
Total: 39 · Buy rate: 64.1%

12-Month Price Target

High

$55.00

Consensus

$31.46

+67.5% upside

Low

$21.00

Median: $27 · Last Close: $18.78

The Tandem Diabetes Care, Inc. (TNDM) analyst consensus is Buy, based on ratings from 39 Wall Street analysts over the past 3 months. The average 12-month TNDM price target is $31.46, representing +67.5% upside from the current price of $18.78.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $31 (67.5%)

Consensus Target

$31.46

67.5% upside

High Target

$55

192.9%

Low Target

$21

11.8%

Current Price

$18.78

as of today

Based on analyst price targets, the TNDM stock price prediction for the next 12 months ranges from $21 to $55. The consensus TNDM price forecast of $31.46 implies 67.5% upside from the current price of $18.78.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$19.725.00%

1-day model range: $19.49–$19.94. Peak: $19.94 (+5.00%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$13-31.3%
2028$11-43.2%
2029$10-48.6%
2030$9-51.3%
2031-52.7%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

BULLISH

Based on 14 technical indicators

64%0%36%
9Buy
0Neutral
5Sell
RSI (14)73.4Overbought
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · TNDM · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$18.84SELL
MA 10$17.66BUY
MA 20$16.01BUY
MA 50$18.11BUY
MA 100$19.94SELL
MA 200$18.36BUY
Current $TNDM · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$18.69BUY
EMA 10$17.93BUY
EMA 20$17.38BUY
EMA 50$18.15BUY
EMA 100$18.94SELL
EMA 200$19.56SELL
Current $TNDM · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Wells Fargo2026-06-01
Upgrade ↑
Equal WeightOverweight
Citigroup2026-05-28
Maintains
NeutralNeutral
B of A Securities2026-05-18
Maintains
NeutralNeutral
Barclays2026-05-11
Maintains
OverweightOverweight
Truist Securities2026-05-11
Maintains
BuyBuy
TD Cowen2026-04-20
Maintains
BuyBuy
Goldman Sachs2026-04-09
Maintains
NeutralNeutral
Truist Securities2026-03-19
Upgrade ↑
HoldBuy
Piper Sandler2026-03-17
Upgrade ↑
NeutralOverweight
Morgan Stanley2026-03-02
Maintains
Equal WeightEqual Weight

Wall Street analysts have recently issued updated ratings on Tandem Diabetes Care, Inc. (TNDM) stock. Of the recent 207 rating actions, 24 were upgrades and 23 were downgrades. 39 analysts currently cover TNDM.

Analyst Recommendation Trends

Buy ratings01↑ +1
Hold ratings101
Sell ratings00

TNDM analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$1.1B

↓ 21.3% YoY

Revenue Next Year

$1.2B

↑ 12.2% YoY

EPS This Year

$-0.68

EPS Next Year

$0.08

↓ 112.1% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast TNDM EPS of $-0.68 for the current fiscal year, based on estimates from 14 analysts. The TNDM revenue forecast is $1.1B for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The TNDM stock forecast is supported by two independent data sources: analyst consensus ratings from 39 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus TNDM price target is $31.46 (+67.5% upside), with an analyst consensus of Buy.

The TNDM short-term stock prediction for tomorrow is $19.72 (+5.00%). The TNDM stock price prediction for 2027 estimates an average of $13. The TNDM stock prediction for 2030 projects a range of $8–$10.

Tandem Diabetes Care, Inc. trades on NASDAQ under the ticker TNDM. The TNDM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 64% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

TNDM forecast · 8 questions

According to 39 Wall Street analysts, the average 12-month TNDM price target is $31.46, with a high forecast of $55.00 and a low of $21.00. The median price target is shown in the chart above when available. This implies +67.5% potential upside from the current price of $18.78.

TNDM price targetWhat is TNDM price targetTNDM analyst price targetTNDM 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.